Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC48D9)

• Drug Name: NG-25 Drug Info
• Synonyms: NG25

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 53340664
  CAS Number: CAS 1315355-93-1
  TTD Drug ID: DMC48D9

Molecule-Related Drug Atlas

Drug(s) Targeting TGF-beta-activated kinase 1 (MAP3K7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID23099093C17d	DMWS7O9	Discovery agent	N.A.	Investigative	[2]
AZ-TAK1	DMD4LGN	Mantle cell lymphoma	2A85.5	Investigative	[3]

Drug(s) Targeting MEK kinase kinase 2 (MAP4K2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quinazoline derivative 9	DMP3QSA	Breast cancer	2C60-2C65	Phase 1	[4]

Drug(s) Targeting Tyrosine-protein kinase CSK (CSK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
936563-93-8	DMPQ2L9	N. A.	N. A.	Patented	[5]

Drug(s) Targeting Tyrosine-protein kinase Lyn (JTK8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bafetinib	DM7586F	Bone disease	FC0Z	Phase 2	[6]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
Alkynyl-substituted pyrimidinyl-pyrrole derivative 1	DMK7DJ2	N. A.	N. A.	Patented	[8]
PMID17600705C23	DMJFOGW	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Proto-oncogene c-Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[10]
Bosutinib	DMTI8YE	Breast cancer	2C60-2C65	Approved	[10]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[11]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[12]
Al3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[13]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[13]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[14]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[15]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[16]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MEK kinase kinase 2 (MAP4K2)	TTQFRP0	M4K2_HUMAN	Inhibitor	[1]
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[1]
TGF-beta-activated kinase 1 (MAP3K7)	TTJQT60	M3K7_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase CSK (CSK)	TTX6F0Q	CSK_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase Lyn (JTK8)	TT1RWNJ	LYN_HUMAN	Inhibitor	[1]

References

• [1] Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
• [2] Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2082).
• [4] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [5] Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors. US9278100.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] National Cancer Institute Drug Dictionary (drug id 596693).
• [8] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
• [9] N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
• [10] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [11] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [12] In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [17] Clinical pipeline report, company report or official report of Turning Point Therapeutics.